Evaluation of the tumor load and adverse reactions of nedaplatin combined with paclitaxel liposome and with paclitaxel treatment of advanced esophageal cancer

摘要

Objective: To evaluate the tumor load and adverse reactions of nedaplatin combined withpaclitaxel liposome and with paclitaxel treatment of advanced esophageal cancer. Methods:A total of 68 patients with advanced esophageal cancer who were treated in our hospitalbetween August 2013 and March 2016 were collected and divided into the paclitaxel liposomegroup (n=34) who received nedaplatin combined with paclitaxel liposome therapy and thepaclitaxel group (n=34) who received nedaplatin combined with paclitaxel therapy accordingto the double-blind randomized control method, and both therapies lasted for 8 weeks.Before treatment and after 8 weeks of treatment, RIA method was used to determine serumesophageal cancer-related tumor marker levels, enzyme-linked immunosorbent assay wasused to determine serum angiogenesis index levels, and flow cytometry was used to measurecellular immunity indexes. Results: Before treatment, the differences in serum tumor markerand angiogenesis index levels as well as cellular immune function indexes were not statisticallysignificant between the two groups. After 8 weeks of treatment, serum tumor markers CY211,CEA, SCC, CA724 and CA125 levels of observation group were lower than those of controlgroup, angiogenesis indexes HIF-α, VEGF and MMP-9 levels were lower than those ofcontrol group, and peripheral blood cellular immunity indexes CD4+ and CD4+/CD8+ levelswere higher than those of control group while CD8+ level was lower than that of control group.Conclusion: Nedaplatin combined with paclitaxel liposome can more effectively reduce thetumor load, causes less adverse effects, and has good curative effect and security.